News and Trends 27 Mar 2019 Artificial Intelligence Could Beat Tumors Resistant to Immunotherapy The French company OSE Immunotherapeutics has signed a partnership to use artificial intelligence to develop treatments for tumors that don’t respond to checkpoint inhibitor drugs. In the last five years, checkpoint inhibitor drugs have become a potentially life-saving option for people that don’t respond to traditional cancer treatments. These antibody drugs have shown promise in […] March 27, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 20 Mar 2019 Czech Cell Therapy Increases Survival in Ovarian Cancer by 62% The Czech biotech company Sotio has shown in a phase II trial that its cellular immunotherapy can decrease the risk of a patient dying from ovarian cancer by 62%. The cell therapy was tested in people with the most severe stages of recurrent ovarian cancer, in combination with second-line chemotherapy when cancer returned after […] March 20, 2019 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 27 Feb 2019 UK Biotech Gets Huge Grant to Launch Off-the-Shelf CAR-T Cancer Therapy to Clinic The UK biotech Cell Medica has received a €7.6M ($8.7M) grant from the Cancer Prevention and Research Institute of Texas to advance an off-the-shelf CAR-T cell therapy that can work not only in blood cancer but also in solid tumors. The funding will help the company to develop a special type of CAR-T cell therapy […] February 27, 2019 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
Interview 27 Feb 2019 How to Make Cancer Drug Resistance Futile For many solid tumors, treatments undergo a cycle: the drugs initially work well, the tumor shrinks, but then becomes resistant again. Stefanie Flückiger-Mangual, CEO of the Swiss biotech Tolremo, believes that this cycle can be stopped. Solid tumors often act like a recurring villain in a TV series. Whatever drug you throw at them, however […] February 27, 2019 - 5 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 11 Feb 2019 Series A to Fund Therapy That Exposes Cancer to Immune System The UK biotech Grey Wolf Therapeutics has raised €11.4M (£10M) to fuel the development of a cancer therapy that flushes tumor cells out of hiding from the immune system. Many approved cancer immunotherapies, such as CAR-T cell therapy and checkpoint inhibitors, have made a big difference for many people with cancer. However, a common problem with […] February 11, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
More News! 8 Feb 2019 Swiss Firm Launches Cancer Test That Gives Results in Minutes Lunaphore Technologies has launched a device for automated testing of cancer tissue samples that gives results in under 30 minutes. Lunaphore has developed a piece of next-generation equipment to perform immunohistochemistry (IHC) tests, a common technique used to find specific cancer biomarkers in tissue samples from cancer patients after a biopsy. The equipment, called LabSat, will […] February 8, 2019 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 4 Feb 2019 Swedish Biotech Receives EU Grant for High-Accuracy Kidney Cancer Test The Swedish biotech Elypta has received a Horizon 2020 grant of €2.4M to fund a clinical trial of a blood and urine test that provides an accurate diagnosis of renal cell carcinoma. The clinical trial aims to validate Elypta’s technology as a monitoring tool in patients who have been treated for the kidney cancer renal […] February 4, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 28 Jan 2019 Update: US District Court Rules Against MorphoSys’ Cancer Immunotherapy Patents Update (01/02/2019): MorphoSys has agreed to end its long-running legal battle with Genmab and Janssen, after the US District Court of Delaware declared three of its cancer immunotherapy patents invalid. MorphoSys began the dispute over Darzalex (daratumumab), Genmab and Janssen’s approved antibody therapy for the blood cancer multiple myeloma. MorphoSys alleged that Darzalex infringed on three of […] January 28, 2019 - 3 minutesmins - By Dani Bancroft Share WhatsApp Twitter Linkedin Email
Startup Scout 18 Jan 2019 This Biotech Turns Rejected Organs Into Drug Testing Models Engitix, a spinout from University College London, makes accurate disease models from human tissue that include the extracellular matrix from outside of the cells, an often overlooked but essential factor in the way cells behave inside our bodies. Mission: To make disease models in the lab that include the extracellular matrix, making them more […] January 18, 2019 - 4 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 15 Jan 2019 Sanofi Obtains License for French Company’s Antibody Engineering Platform Sanofi has signed a licensing deal with French biotech Biomunex, whose antibody technology has the potential to develop new immunotherapy treatments for cancer and infectious diseases. Sanofi will give Biomunex an upfront payment, along with further installments upon achieving key development milestones. The amounts have not been disclosed. Biomunex is able to make a wide variety […] January 15, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
Startup Scout 11 Jan 2019 This Company Automates Cancer Research from Bench to Bar Charts In the academic city of Oxford, UK, the company Arctoris is working to make life easier for cancer lab researchers, letting them ‘order’ experiments online using its robotic facilities and data analysis tools. Mission: To cut down researchers’ workloads by automating cellular, molecular, and data analysis techniques in cancer research. As any molecular biologist will […] January 11, 2019 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 7 Jan 2019 Sanofi Invests €80M in mRNA Cancer Vaccine Company Sanofi is to make an €80M equity investment in the German biotech BioNTech, and the two have agreed to co-develop a cancer vaccine based on injecting messenger RNA into solid tumors. This agreement is an extension of Sanofi and BioNTech’s collaboration, which began in 2015. The two companies will continue to co-develop and co-commercialize a candidate […] January 7, 2019 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email